NYBCe acquires development, manufacturing facilities from Talaris Therapeutics

New York Blood Center Enterprises, NYBCe, and Talaris Therapeutics announced NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe’s Comprehensive Cell Solutions vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States, capable of serving the biopharma industry and large hospital systems.